CAJ | 학술논문

芳香化酶抑制剂（AI）是绝经后乳腺癌激素受体阳性患者内分泌治疗的主要药物，但其不良反应骨关节疼痛（AIA）潜在影响这类药物的临床实用。目前关于AIA的发生机制并不十分清楚，文献报道与雌激素水平下降、免疫指标异常、腱鞘变化及关节积液等有关。在临床中重视并选择适当手段治疗AIA，减少AIA的发生，有助于提高使用AI的依从性。
방향화매억제제（AI）시절경후유선암격소수체양성환자내분비치료적주요약물，단기불량반응골관절동통（AIA）잠재영향저류약물적림상실용。목전관우AIA적발생궤제병불십분청초，문헌보도여자격소수평하강、면역지표이상、건초변화급관절적액등유관。재림상중중시병선택괄당수단치료AIA，감소AIA적발생，유조우제고사용AI적의종성。
Aromataseinhibitors(AI)aretheleadingcarefortheadjuvanttreatmentofhormone responsive carcinoma of the breast as demonstrated in a number of large international phase III randomised tri-als.Aromatase inhibitor-associated arthralgia (AIA )was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice.The pathogenesis of AIA is not very clear currently,with the cause of most research focusing on estrogen deprivation,immune abnormalities,tenosy-novial changes and joint effusions.It is extremely urgent that we evaluate this syndrome and select appropriate therapeutic strategies to reduce the incidence of AIA,thereby improving breast cancer-related outcomes.